Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol

Journal of Pharmacological and Toxicological Methods

Volumn 59, Issue 1, 2009, Pages 13-20

  Bertera, Facundo Martín ^a   Di Verniero, Carla Andrea ^a   Mayer, Marcos Alejandro ^a   Bramuglia, Guillermo Federico ^a   Taira, Carlos Alberto ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Blood pressure; Carvedilol; Chloralose; Heart rate; L NAME; Pharmacokinetic pharmacodynamic modeling; Urethane

Indexed keywords

CARVEDILOL; CHLORALOSE; ETHER; N(G) NITROARGININE METHYL ESTER; URETHAN;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; HYPERTENSION; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANESTHESIA; ANIMALS; AREA UNDER CURVE; BLOOD PRESSURE; CARBAZOLES; CHLORALOSE; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HALF-LIFE; HEART RATE; HYPERTENSION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; NG-NITROARGININE METHYL ESTER; PROPANOLAMINES; RATS; RATS, WISTAR; SOLUTIONS; URETHANE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 58149459790     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.10.001     Document Type: Article

References (42)

1. Aimone L.D. Overview of pharmacokinetics. Current Protocols in Pharmacology (2005) 7.1.1-7.1.26
2. Augustyniak R.A., Victor R.G., Morgan D.A., and Zhang W. L-NAME- and L-NAMEADMA-induced sympathetic neural activation in conscious rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 290 (2006) R726-R732
3. Authier S., Tanguay J.F., Fournier S., Gauvin D., Legaspi M., Chaurand F., et al. Conscious and anesthetized non-human primate safety pharmacology models: Hemodynamic sensitivity comparison. Journal of Pharmacological and Toxicological Methods 580 (2008) 94-98
4. Baek I.H., Yun M.H., Yun H.Y., and Kwon K.I. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Archives of pharmacal research 31 (2008) 814-821
5. Bertera F.M., Mayer M.A., Opezzo J.A., Taira C.A., and Höcht C. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension. Journal of Pharmacological and Toxicological Methods 57 (2008) 212-219
6. Bertera F.M., Mayer M.A., Opezzo J.A.W., Taira C.A., Bramuglia G.F., and Höcht C. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study. Journal of Pharmacological and Toxicological Methods 56 (2007) 290-299
7. Biancardi V.C., Bergamaschi C.T., Lopes O.U., and Campos R.R. Sympathetic activation in rats with l-NAME-induced hypertension. Brazilian Journal of Medical and Biological Research 40 (2007) 401-408
8. Bousquet P., Gaertner M., Feldman J., and Bloch R. Variations in the effect of clonidine on arterial pressure in rats in the presence of various anesthetics. Comptes rendus des séances de la Société de biologie et de ses filiales 171 (1977) 1129-1133
9. Carreira R.S., Monteiro P., Gon Alves L.M., and Providência L.A. Carvedilol: just another beta-blocker or a powerful cardioprotector?. Cardiovascular & hematological disorders drug targets 6 (2006) 257-266
10. Carruba M.O., Bondiolotti G., Picotti G.B., Catteruccia N., and Da Prada M. Effects of diethyl ether, halothane, ketamine and urethane on sympathetic activity in the rat. European Journal of Pharmacology 134 (1987) 15-24
11. Claassen V. Anaesthesia. In: Claassen V. (Ed). Neglected factors in pharmacology and neuroscience research (1994), Elsevier, Amsterdam 382-421
12. D'Argenio D.Z., and Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software (1997), Biomedical Simulations Resource, Los Angeles
13. Di Verniero C.A., Silberman E.A., Mayer M.A., Opezzo J.A., Taira C.A., and Höcht C. In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. Journal of Cardiovascular Pharmacology 51 (2008) 532-541
14. Frishman W.H. Carvedilol. The New England Journal of Medicine 339 (1998) 1759-1765
15. Fujimaki M. Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality 4 (1992) 148-154
16. Gerová M. Nitric oxide-compromised hypertension: facts and enigmas. Physiological Research 49 (2000) 27-35
17. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed. (1982), Marcel Dekker Inc, New York
18. Gumbleton M., Nicholls P.J., and Taylor G. Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. Journal of Pharmacy and Pharmacology 42 (1990) 693-697
19. Himori N., and Ishimori T. Different responses to beta-adrenoceptor blocking drugs of the blood pressure and heart rate in the urethane-anesthetized dog and rat. Japan Journal of Pharmacology 47 (1988) 71-80
20. Höcht C., Di Verniero C., Opezzo J.A.W., Bramuglia G.F., and Taira C.A. Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn-Schmiedeberg's Archives of Pharmacology 373 (2006) 310-318
21. Höcht C., Di Verniero C., Opezzo J.A.W., and Taira C.A. Applicability of microdialysis as a technique for pharmacokinetic-pharmacodynamic (PK-PD) modeling of antihypertensive beta-blockers. Journal of Pharmacological and Toxicological Methods 52 (2005) 244-250
22. Höcht C., Mayer M.A., Opezzo J.A.W., Bertera F.M., and Taira C.A. Pharmacokinetic pharmacodynamic modeling of antihypertensive drugs: From basic research to clinical practice. Current Hypertension Reviews 4 (2008) 289-302
23. Höcht C., Opezzo J.A., and Taira C.A. Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. Pharmacology 70 (2004) 23-30
24. Höcht C., Opezzo J.A.W., Bramuglia G.F., and Taira C.A. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling. Expert Opinion on Drug Discovery 1 (2006) 289-301
25. Höcht C., Opezzo J.A.W., and Taira C.A. Microdialysis in drug discovery. Current Drug Discovery Technologies 1 (2004) 269-285
26. Ishida K., Taira S., Morishita H., Kayano Y., Taguchi M., and Hashimoto Y. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biological & Pharmaceutical Bulletin 31 (2008) 1297-1300
27. Keating G.M., and Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 63 (2003) 1697-1741
28. Kohno T., Yoshikawa T., Yoshizawa A., Nakamura I., Anzai T., Satoh T., et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovascular Drugs and Therapy 19 (2005) 347-355
29. Kramer K., and Remie R. Measuring blood pressure in small laboratory animals. Methods in molecular medicine 108 (2005) 51-62
30. Le Noble J.L., Struyker-Boudier H.A., and Smits J.F. Differential effects of general anesthetics on regional vasoconstrictor responses in the rat. Archives internationales de pharmacodynamie et de thérapie 289 (1987) 82-92
31. Loch J.M., Potter J., and Bachmann K.A. The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 50 (1995) 146-153
32. Meneguz A., Fortuna S., Lorenzini P., and Volpe M.T. Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo. Experimental and Toxicological Pathology 51 (1999) 392-396
33. Neugebauer G., and Neubert P. Metabolism of carvedilol in man. European Journal of Drug Metabolism and Pharmacokinetics 16 (1991) 257-260
34. Pechánová O., Dobesová Z., Cejka J., Kunes J., and Zicha J. Vasoactive systems in l-NAME hypertension: the role of inducible nitric oxide synthase. Journal of Hypertension 22 (2004) 167-173
35. Ruffolo Jr. R.R., Boyle D.A., Venuti R.P., and Lukas M.A. Preclinical and clinical pharmacology of carvedilol. Journal of Human Hypertension 7 Suppl 1 (1993) S2-S15
36. Schaefer W.H., Politowski J., Hwang B., Dixon Jr. F., Goalwin A., Gutzait L., et al. Metabolism of carvedilol in dogs, rats, and mice. Drug Metabolism and Disposition 26 (1998) 958-969
37. Smith T.L., and Hutchins P.M. Anesthetic effects on hemodynamics of spontaneously hypertensive and Wistar-Kyoto rats. American Journal of Physiology 238 (1980) H539-H544
38. Sponer G., Bartsch W., Strein K., Müller-Beckmann B., and Böhm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. Journal of Cardiovascular Pharmacology 9 (1987) 317-327
39. Tenero D.M., Henderson L.S., Campanile A.M., Baidoo C.A., and Boyle D. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. American Journal of Cardiology 98 7A (2006) 27L-31L
40. Terao N., and Shen D.D. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. The Journal of Pharmacological and Experimental Therapeutics 227 (1983) 369-375
41. van Steeg T.J., Freijer J., Danhof M., and de Lange E.C. Pharmacokinetic-pharmacodynamic modelling of s(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. British Journal of Pharmacology 151 (2007) 356-366
42. Zicha J., Dobesová Z., and Kunes J. Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in l-NAME hypertensive rats. Hypertension Research 29 (2006) 1021-1027